Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

Presentations highlight data supporting FILSPARI ® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO , May 09, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. , (Nasdaq: TVTX) today announced that the Company will

View Full Press Release